Abstract
The present invention relates generally to compositions useful in therapies involving the selective destruction of tumor cells in vivo. In particular, this invention relates to a conjugate which comprises a target recognition segment and an active cytotoxic segment. The target recognition segment comprises a receptor specific to NK cells, wherein the receptor binds to a cellular ligand expressed on the surface of a tumor cell, and the active segment comprises an agent capable of exerting a cytotoxic effect on the tumor cell. The target recognition segment derived form the natural killer receptor NKp30 has been found to be particularly effective in vivo.
Original language | English |
---|---|
Patent number | WO2004053054 |
IPC | C12N 15/ 62 A I |
Priority date | 9/12/02 |
State | Published - 24 Jun 2004 |